BG Medicine, Inc. Welcomes Presentation of Clinical Data on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BG Medicine, Inc. Welcomes Presentation of Clinical Data on Galectin-3 Testing at the American Heart Association 2014 Scientific Sessions Conference

WALTHAM, Mass., Nov. 20, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq: BGMD ), the developer of the BGM Galectin-3 ® Test, announced today that 17 abstracts reporting independent research that investigates galectin-3 testing in various cardiovascular diseases have been presented at the American Heart Association's 2014 Scientific Sessions and Resuscitation Science Symposium, which was held in Chicago, Illinois during November 15-19, 2014.

"The clinical research presented on galectin-3 testing spans a broad spectrum of cardiovascular disease, from galectin-3 testing to identify heart failure patients at risk of near-term hospital readmissions, to galectin-3 testing for fibrosis-related disorders associated with the heart," said Dr. Paul R. Sohmer, President and CEO of BG Medicine, Inc. "Included among the abstracts presented were the results of preclinical and clinical research studies in which galectin-3 testing was studied alone and in combination with other biomarkers."

Abstracts from all presentations made at the conference are being published in the November 25, 2014 issue of the journal Circulation [1], and include the following:

Abstract No. 19799: "The Addition of Galectin-3 Significantly Improves Upon the Ability of Discharge BNP to Predict 60 Day Readmission for Acute Decompensated Heart Failure." Presented by clinicians from the Washington University School of Medicine in St. Louis, this study of patients discharged after a hospitalization for acute heart failure found that galectin-3 testing, performed using the BGM Galectin-3 ® Test, was able to significantly improve the identification of those patients who were unexpectedly re-hospitalized within 60 days of their discharge. The clinicians concluded that "This data will be useful to help identify those at-risk of re-admission and aid in efficiently implementing appropriate interventions to reduce re-admission rates."

Abstract No. 18557: "Low Galectin-3 Identifies Heart Failure Patients at Minimal Risk for Death or Rehospitalization." This analysis of a cohort of 592 patients, presented by a group of heart failure clinicians from the United States and Europe, concluded that low values of galectin-3 testing, as performed by the BGM Galectin-3 ® Test, were able to identify heart failure patients who were at minimal risk of repeated hospital admissions, within 30, 90 and 180 days after an initial hospitalization for heart failure. The clinical prediction provided by galectin-3 testing was significantly additive to other important patient parameters including kidney function, B-type natriuretic peptide level, and cardiac pumping capacity.

Abstract No. 17390: "Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study." Performed by researchers at the Massachusetts General Hospital, New York-Presbyterian Hospital, and the Weill Cornell Medical College, this clinical research study of 132 patients undergoing cardiac resynchronization therapy and followed for 2 years demonstrated that galectin-3 testing, to assess levels of tissue fibrosis, assisted in identifying patients with improved functional mitral regurgitation after device placement. Cardiac resynchronization therapy, or CRT, also referred to as biventricular pacing, involves the implantation of a specialized pacemaker device to attempt to improve the heart's rhythm and alleviate symptoms associated with arrhythmia in heart failure.

Abstract No. 18665: "Galectin-3 Predicts Left Ventricular Ejection Fraction After Myocardial Infarction." In this study of 380 patients who underwent coronary angioplasty after a myocardial infarction, or heart attack, clinicians reported that elevated levels of galectin-3 at baseline were a strong and independent predictor of those patients who, in the following 4 months, would experience a significant deterioration of cardiac ejection fraction, a measure of the pumping capacity of the filled ventricle of the heart. The researchers further concluded that the pro-fibrotic effects of high levels of galectin-3 after a heart attack may result in the detrimental decline in the pumping capacity of the heart that was observed.

Abstract No. 15237: "Serum Galectin-3 Level Predicts Late Recurrence Following Cryoballoon-based Pulmonary Vein Isolation in Lone Atrial Fibrillation Patients." In this study of 100 patients undergoing treatment for atrial fibrillation, a common cardiac arrhythmia, or irregular heartbeat, associated with fibrosis in the heart, elevated pre-procedural levels of galectin-3 were found to be a significant predictor for the identification of patients who experienced recurrence of their atrial fibrillation 12 months after the initial procedure.

Other abstracts presented included reports on preclinical research in which galectin-3 was studied in various animal models, clinical research in which galectin-3 was studied in stroke, atrial fibrillation, after aortic valve implantation, as a predictor of myocardial fibrosis in Kawasaki Disease, and, in combination with other biomarkers, in hypertensive heart disease, myocardial infarction, and heart transplants.

About the BGM Galectin-3® Test

The BGM Galectin-3® Test is cleared by the U.S. FDA as an aid in assessing the prognosis of patients diagnosed with chronic heart failure when used in conjunction with clinical evaluation.

The BGM Galectin-3® Test is CE Marked and is available in Europe as an aid in assessing the prognosis of patients diagnosed with acute and chronic heart failure when used in conjunction with clinical evaluation. It is also CE Marked for adults as an aid in assessing the risk of new onset heart failure.

About Galectin-3 and Heart Failure

Galectin-3 is a protein that is involved in fundamental disease processes including the development of fibrosis in organ tissues, and cardiac remodeling, which may lead to the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of hospitalization or death. The BGM Galectin-3® Test is to be used as an aid in assessing the prognosis of patients with chronic heart failure, in conjunction with clinical evaluation. For more information please visit www.BG-Medicine.com .

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq: BGMD ), the developer of the BGM Galectin-3® Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.BG-Medicine.com .

The BG Medicine Inc. logo is available for download here .

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical utility of galectin-3 testing and the predictive and prognostic value of galectin-3 as a biomarker of fibrosis and cardiac remodeling. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, among other things, the factors discussed under the heading "Risk Factors" contained in BG Medicine's annual report and quarterly reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and BG Medicine disclaims any obligation to update the information contained in this press release as new information becomes available.

References:

[1] Abstracts From the American Heart Association 2014 Scientific Sessions and Resuscitation Science Symposium. Circulation. Volume 130, Issue 22, Supplement 2; November 25, 2014.

Stephen Hall, EVP & Chief Financial Officer (781) 890-1199

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 130

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 48

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 63

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 84

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 113

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 98

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Vusion's 2030 Plan Puts Recurring Revenue First At Scale

Updated Category News Views 77

Shelf labels are not exactly romance, yet Vusion has turned them into a serious growth machine. The 2030 plan is not really about hanging more electronic displays in aisles; it is about making those displays, sensors and store connections produce software and service revenue for years. That is the part of this story worth watching. The Hardware Base Is Becoming the Hook...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 92

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading

Top 5 Most Recently Viewed Articles

China's Investment Landscape Transformed by Market Reforms

Updated Category News Views 451

China's Market Value Reforms Enhancing Investment Confidence Recent developments in China’s market management are poised to reshape the landscape of investment, significantly boosting investor confidence. UBS analysts emphasize that these new measures represent a critical shift, aiming to cultivate a healthier environment for both domestic and foreign investors. Key...

Continue Reading
CI Financial Sees Significant Growth with Total Assets of $525B

Updated Category News Views 134

CI Financial Achieves Impressive Total Assets for October CI Financial Corp. (“CI”) (TSX: CIX) has recently announced a remarkable total asset figure of $525.3 billion. This impressive number celebrates a multifaceted asset landscape, including asset management assets totaling $136.1 billion, Canadian wealth management assets of $100.4 billion, Canadian custody assets...

Continue Reading
Carlyle Credit Income Fund Plans Second Quarter Results Update

Updated Category News Views 193

Carlyle Credit Income Fund Plans Second Quarter Results Update The Carlyle Credit Income Fund, often referred to as CCIF, has exciting news. The Fund is set to unveil its financial performance for the second quarter following market close on a specific upcoming Tuesday in May. This announcement represents a crucial moment for stakeholders and potential investors eager to...

Continue Reading
Lithia Motors Boosts Earnings: Price Target Climbs Significantly

Updated Category News Views 75

Lithia Motors Sees Price Target Hike After Strong Earnings Recently, Lithia Motors (NYSE: LAD) garnered attention in the financial markets as Stephens, a prominent financial services company, announced an increase in its price target for the automaker. The target officially rose from $360 to $405. This update follows a robust earnings report for the third quarter,...

Continue Reading
VFC Corporation Achieves 52-Week High: What it Means for Investors

Updated Category News Views 95

VFC Corporation Achieves New Market Heights In a remarkable surge, VFC Corporation's stock has reached a significant milestone by hitting a 52-week high at $20.7. This impressive figure is a clear indication of a substantial turnaround, demonstrating a remarkable 23.84% increase over the last year. Confidence among investors has rebounded as they recognize the apparel...

Continue Reading